The indications for 68Ga-PSMA PET/CT included biochemical failure (n = 270, 61%), staging of high-risk disease (n = 112, 25%), assessment of response to anti-cancer therapy (n = 30, 7%), follow-up with no evidence of clinical, biochemical or imaging suspicious for recurrence on (n = 22, 5%) and suspected bone metastases on other imaging modalities performed as routine assessment (n = 11, 2%) (Table 1). The gene discussed is FOLH1; the disease is cancer.